会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof
    • 四氢喹唑啉-2,4-二酮及其治疗用途
    • US06521630B1
    • 2003-02-18
    • US09650486
    • 2000-08-29
    • Anton Franz Joseph FliriTodd William ButlerRandall James GallaschunJohn Anthony RaganBrian Patrick Jones
    • Anton Franz Joseph FliriTodd William ButlerRandall James GallaschunJohn Anthony RaganBrian Patrick Jones
    • A61K31517
    • C07D401/14C07D401/04C07D401/06C07D401/08C07D401/12
    • The present invention relates to tetrahydroquinazoline-2,4-diones derivatives of the formula (I): pharmaceutically acceptable salts thereof, wherein A is (CH2)n where n is equal to 0, 1 or 2; U is CH2, NH, or NR3, R1 and R2 are selected independently from H, (C1-C6)alkyl, Cl, F, CN, nitro, CF3, —NHC(O)R6 and —OR7, or R1 and R2, together with the atoms to which they are attached, form a carbocyclic or heterocyclic five- or six-membered ring, R3 is selected from the group consisting of H, (C1-C6)malkyl, C(═O)—(C1-C6)alkyl, where m=1 or 2; R4 and R5 are selected from H, (C1-C6)alkyl, Cl, F, —CF3, —CN, —NHC(═O)R6, —OR7, a 5-to 7-membered aryl or heteroaryl ring, where m, R6 and R7 are as defined above; and R6 and R7 are selected independently from H, (C1-C6)alkyl or a 5- to 7-membered aryl or heteroaryl ring; V is CH, CR3, or N; W is CH2, C(O), or S(O)2; X is C or N; and Y is CH, CR1,CR2, or N. The invention also relates to pharmaceutical compositions containing the same and to methods of use thereof, including in the inhibition of serotonin reuptake, the inhibition of the binding of 5-HT2A serotonin receptors and the treatment of diseases, conditions or disorders of the central nervous system. Further, the present invention is also directed to methods for the preparation of 4-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)-propyl-1,2,3,4-tetrahydroquinazoline-2,4-dione compounds and intermediates useful thereof.
    • 本发明涉及式(I)的四氢喹唑啉-2,4-二酮衍生物:其药学上可接受的盐,其中A是(CH2)n,其中n等于0,1或2; U是CH 2,NH或NR 3,R 1和R 2独立地选自H,(C 1 -C 6)烷基,Cl,F,CN,硝基,CF 3,-NHC(O)R 6和-OR 7或R 1和R 2, 与其连接的原子一起形成碳环或杂环的五元或六元环,R 3选自H,(C 1 -C 6)烷基,C(= O) - (C 1 -C 6) )烷基,其中m = 1或2; R4和R5选自H,(C1-C6)烷基,C1,F,-CF3,-CN,-NHC(= O)R6,-OR7,5-7元芳基或杂芳基环,其中m ,R6和R7如上所定义; 并且R 6和R 7独立地选自H,(C 1 -C 6)烷基或5至7元芳基或杂芳基环; V是CH,CR 3或N; W是CH 2,C(O)或S(O)2; X为C或N; 并且Y是CH,CR1,CR2或N.本发明还涉及含有该组合物的药物组合物及其使用方法,包括抑制5-羟色胺再摄取,抑制5-HT2A 5-羟色胺受体的结合和 治疗中枢神经系统的疾病,病症或病症。 此外,本发明还涉及制备4-(4-苯基-1,2,3,6-四氢吡啶-1-基) - 丙基-1,2,3,4-四氢喹唑啉-2, 4-二酮化合物及其有用的中间体。